Top 10 Most Licensable Oncology Projects to Watch
Since 2007, executives in the Business Development practice at Campbell Alliance have collaborated with Windhover to choose the "Top 10 Most Licensable Oncology Projects to Watch."
In 2011, the oncology top 10 was narrowed from a field of over 1,700 oncology assets using a strict set of judging criteria. The selected projects represent what are considered the most attractive licensable oncology opportunities the industry has to offer. Specifically, the selection team focused on what are considered “hot areas” in oncology: those with transformational, nascent therapies where the potential for differentiation is high. Conjugated antibody, cancer metabolism, and immuno-oncology technologies dominated the list this year.
According to Jonathon Fendelman, Senior Practice Executive, the selection team’s approach this year was to look at differentiated molecular pathways and technologies. While these targeted approaches tend to address smaller patient populations initially, a great deal of potential exists for add-on indications, which makes them attractive licensing opportunities. Further, strong differentiation raises the likelihood of reimbursement post-approval, which is key in an increasingly payer-driven market.
2011 Top 10 Most Licensable Oncology Projects to Watch
|
Company
|
Asset/Compound
|
Location
|
Website
|
|
Advaxis
|
ADXS-HPV
|
US/New Jersey
|
www.advaxis.com
|
|
Altor
|
ALT-801
|
US/Florida
|
www.altorbioscience.com
|
|
Aveo
|
Ficlatuzumab
|
US/Massachusetts
|
www.aveopharma.com
|
|
Biotest AG
|
BT-062
|
Germany
|
www.biotest.com
|
|
Celldex
|
CDX-011
|
US/Massachusetts
|
www.celldextherapeutics.com
|
|
Endocyte
|
EC145
|
US/Indiana
|
www.endocyte.com
|
|
ImmunoCellular Therapeutics
|
ICT-107
|
US/California
|
www.imuc.com
|
|
Immune System Therapeutics
|
MDX 1097
|
Australia
|
www.istl.com.au
|
|
Neogenix Oncology
|
Ensituximab/NPC-1C
|
US/New York
|
www.neogenix.com
|
|
Ruga
|
STF-31
|
US/California
|
www.rugacorp.com
|
Campbell Alliance works with pharmaceutical and biotech companies to
- Develop an oncology portfolio strategy
- Determine the value of an asset or group of assets
- Identify, evaluate, and pursue potential partners
- In-license and out-license products
- Facilitate transactions
Please click here to request more information on the oncology top 10 or to discuss how we might be able to help your company understand the market for your oncology portfolio.
Thought Leadership
The oncology market has changed dramatically over the last 10 years. These changes have been brought about by 10 transformative trends, the effects of which will only intensify in the coming decade. Campbell Alliance’s Landmark Study, the ONC Study, analyzes these trends and explains their implications for leaders in the pharmaceutical and biotech industry...